Amphetamine concentrations in human urine following single-dose administration of the calcium antagonist prenylamine-studies using fluorescence polarization immunoassay (FPIA) and GC-MS.

Prenylamine (R,S-N-(3,3-diphenylpropyl-methyl-2-phenethylamine), a World Health Organization class V calcium antagonist, is known to be metabolized to amphetamine. In this study, amphetamine concentrations after a single-dose administration of prenylamine were determined to check if they reached values that could be of analytical and/or pharmacological importance in clinical and forensic toxicology. Enantiomeric composition of amphetamine was also studied. Five volunteers received a single 120-mg oral dose of prenylamine. Urine samples were analyzed using the Abbott TDx immunoassay Amphetamine/Methamphetamine II and using our routine systematic toxicological analysis (STA) gas chromatography-mass spectrometry (GC-MS) procedure. For quantitation purposes, GC-MS was used in the selected-ion monitoring (SIM) mode (ions m/z 118, 122, 240, 244) after solid-phase extraction (Isolute Confirm HCX) and derivatization (heptafluorobutyric anhydride). Amphetamine-d5 was used as internal standard (IS). Chiral separation of the heptafluorobutyrated amphetamine enantiomers was achieved using an Astec Chiraldex G-PN column. The TDx results showed a great variability for the different volunteers. A urine sample of one volunteer showed results as high as 3200 ng/mL, whereas the urine samples of another volunteer never gave results greater than the TDx detection limit (100 ng/mL). Using the STA procedure, the presence of amphetamine could be confirmed in all urine samples with TDx results greater than the cutoff value (300 ng/mL). Using the GC-MS SIM method, amphetamine concentrations up to 1280 ng/mL were determined. Chiral analysis revealed that both enantiomers of amphetamine were present in the samples with a surplus of the S(+)-enantiomer in the early phase of excretion. Forensic implications are discussed.

[1]  H. Maurer Systematic toxicological analysis of drugs and their metabolites by gas chromatography-mass spectrometry. , 1992, Journal of chromatography.

[2]  H. Maurer,et al.  Identification and differentiation of benzodiazepines and their metabolites in urine by computerized gas chromatography-mass spectrometry. , 1987, Journal of chromatography.

[3]  H. Maurer,et al.  Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[4]  H. Maurer,et al.  Mass spectral and GC data of drugs, poisons, and their metabolites , 1985 .

[5]  H. Maurer On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. , 1996, Therapeutic drug monitoring.

[6]  Karl Pfleger,et al.  Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites: Part 3 mass spectra (m/z222 to 777 amu). , 1992 .

[7]  R. Bayer,et al.  Basic mechanisms underlying prenylamine-induced 'torsade de pointes': differences between prenylamine and fendiline due to basic actions of the isomers. , 1988, Current medical research and opinion.

[8]  H. Maurer,et al.  Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites. Part 1: methods, tables, indexes. , 1992 .

[9]  E. Mutschler,et al.  Single- and multiple-dose pharmacokinetics of R-(−)- and S-(+)-prenylamine in man , 2004, European Journal of Clinical Pharmacology.

[10]  Thomas Layloff,et al.  Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies , 1992, Pharmaceutical Research.

[11]  H. Maurer,et al.  Identification and differentiation of beta-blockers and their metabolites in urine by computerized gas chromatography-mass spectrometry. , 1986, Journal of chromatography.

[12]  A. Fleckenstein History of Calcium Antagonists , 1983, Circulation research.

[13]  H. Maurer Identification and differentiation of barbiturates, other sedative-hypnotics and their metabolites in urine integrated in a general screening procedure using computerized gas chromatography-mass spectrometry. , 1990, Journal of chromatography.

[14]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[15]  H. Maurer,et al.  Screening procedure for detection of antidepressants of the selective serotonin reuptake inhibitor type and their metabolites in urine as part of a modified systematic toxicological analysis procedure using gas chromatography-mass spectrometry. , 2000, Journal of analytical toxicology.

[16]  H. Maurer,et al.  Screening procedures for simultaneous detection of several drug classes used for high throughput toxicological analyses and doping control. A review. , 2000, Combinatorial chemistry & high throughput screening.

[17]  C. J. Schmitt,et al.  Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) in toxicological analysis. Studies on the detection of clobenzorex and its metabolites within a systematic toxicological analysis procedure by GC-MS and by immunoassay and studies on the detection of alp , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[18]  M. Lehmann,et al.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. , 1993, JAMA.

[19]  I. Vernaleken,et al.  Studies on the metabolism and toxicological detection of the amphetamine-like anorectic mefenorex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[20]  M. Eichelbaum,et al.  Metabolism of DL-[14C]prenylamine in man. , 1977, Biomedical mass spectrometry.

[21]  H. Maurer,et al.  Screening for Detection of New Antidepressants, Neuroleptics, Hypnotics, and Their Metabolites in Urine by GC-MS Developed Using Rat Liver Microsomes , 2001, Therapeutic drug monitoring.

[22]  H. Maurer,et al.  Screening procedure for the detection of opioids, other potent analgesics and their metabolites in urine using a computerized gas chromatographic-mass spectrometric technique , 1984 .

[23]  H. Maurer,et al.  Toxicological detection of pholcodine and its metabolites in urine and hair using radio immunoassay, fluorescence polarisation immunoassay, enzyme immunoassay and gas chromatography-mass spectrometry , 2005, International Journal of Legal Medicine.

[24]  A. Vermeulen,et al.  Double-Blind Comparison of Prenylamine and Penbutolol in Patients with Angina Pectoris , 1985, The Journal of international medical research.

[25]  K. Kovar,et al.  Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. , 1996, Journal of chromatography. B, Biomedical applications.

[26]  Thomas Layloff,et al.  Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies , 1992 .